MoonLake Immunotherapeutics explores sale | Reuters News Agency
Business & FinanceDealsHealth

MoonLake Immunotherapeutics explores sale

MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition.

Market Impact

MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday, giving the company a market value of $3.3 billion.

Article Tags
Topics of Interest: Business & FinanceDealsHealth
Type: Reuters Best
Sectors: Business & FinancePharmaceuticals & Healthcare
Regions: Europe
Countries: Switzerland
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Significant National Story
Sign up for email updates
Sign up for email updates